Physician profile
Rotem Amir
NPI 1871603290
$12,611.37
in general payments reported to CMS, 2019-2025
32 companies · $8,552 in 2025
The $8,552 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,272 · 2020: $619 · 2021: $182 · 2022: $560 · 2023: $253 · 2024: $175 · 2025: $8,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $8,000 · Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $8,000.00 |
| Food and Beverage | $979.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $8,534.19 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Novo Nordisk INC | $1,281.70 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $273.23 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $251.74 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $205.08 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $184.53 | 2019-2020 | |
| Valeritas, INC. | $179.90 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $162.40 | 2023-2024 | Imcivree, Imcivree |
| Zealand Pharma US, INC. | $127.10 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $124.62 | 2019 | |
| Astellas Pharma US INC | $101.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $96.91 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $95.73 | 2019-2022 | |
| Intuitive Surgical, INC. | $85.89 | 2023 | Da Vinci Surgical System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $84.74 | 2019-2020 | |
| Vivus LLC | $81.66 | 2019-2022 | |
| Melinta Therapeutics, LLC | $80.54 | 2019 | |
| Zyla Life Sciences, INC. | $69.48 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $57.35 | 2019 | |
| Pfizer INC. | $54.71 | 2019 | |
| Grifols USA, LLC | $49.89 | 2019 | |
| Allergan, INC. | $40.66 | 2019-2020 | |
| Radius Health, INC. | $33.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.25 | 2019 | |
| Amgen INC. | $26.94 | 2019 | |
| Abbott Laboratories | $20.50 | 2024 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $20.43 | 2019 | |
| Medtronic Minimed, INC. | $18.19 | 2019 | |
| Hologic Sales and Service, LLC | $17.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rotem Amir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.